Fig. 1
From: A multicenter real-world evidence study in the Swiss treatment landscape of chronic myeloid leukemia
Treatment journey for each patient (n = 63), grouped by initial TKI and duration of follow-up duration. Sixty months of follow-up are shown; the total duration of follow-up and number of switches is shown on the right. Each row represents a single patient. Vertical orange dotted lines indicate target timelines for milestones according to the most commonly used guidelines (at 3, 6, and 12 months for ELN, and 3, 6, 12 and > 18 months for ESMO guidelines). See also Table S2 in the Supplementary Information for a list of adverse events leading to TKI discontinuation